` RDHL (Redhill Biopharma Ltd) vs S&P 500 Comparison - Alpha Spread

RDHL
vs
S&P 500

Over the past 12 months, RDHL has underperformed S&P 500, delivering a return of -80% compared to the S&P 500's 9% growth.

Stocks Performance
RDHL vs S&P 500

Loading
RDHL
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RDHL vs S&P 500

Loading
RDHL
S&P 500
Difference
www.alphaspread.com

Performance By Year
RDHL vs S&P 500

Loading
RDHL
S&P 500
Add Stock

Competitors Performance
Redhill Biopharma Ltd vs Peers

S&P 500
RDHL
LLY
JNJ
NOVO B
ROG
Add Stock

Redhill Biopharma Ltd
Glance View

Market Cap
4.2m USD
Industry
Pharmaceuticals

RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.

RDHL Intrinsic Value
8.6 USD
Undervaluation 79%
Intrinsic Value
Price
Back to Top